CST Ltd. is an Israeli-based private company, established in 2018. Our vision Develop an innovative gene and cell therapy for acute myocardial ischemia following acute heart attack to save millions of patients. Mission Add a cardio-protective treatment to the standard of care. The aim of the current project is to prevent or to restrict cardiac scar tissue following acute heart attack and thus to reduce the incidence of heart failure (HF). Our vision is to offer a personalized cell therapy treatment, that will save lives and increase life expectancy following a heart attack.
Company Details
- Founded
- 2018
- Address
- Petah Tikvah, 4918002, Il
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- crispr, stem cells, personalized gene therapy, tissu engineering, cell therapy, heart attack, myocardial ischemia, chronic heart faluire, ischemic heart disease, therapy treatment based on autologous (self) stem cells, startup, patent.
- HQ
- Petah Tikvah
Crispr Stem & Therapeutics Ltd. Questions
Crispr Stem & Therapeutics Ltd.'s website is http://www.crisprstemtherapeutics.com
Crispr Stem & Therapeutics Ltd.'s LinkedIn profile is https://il.linkedin.com/company/crispr-stem-therapeutics-ltd
Crispr Stem & Therapeutics Ltd.'s industry is
Biotechnology Research
Crispr Stem & Therapeutics Ltd.'s top competitors are
Neurogenesis Bio Inc.,
Intellia Therapeutics, Inc.,
Epeius Pharma,
Biocep,
Tessera Therapeutics,
Targetgene Biotechnologies Ltd,
Lepton Pharmaceuticals,
Beam Therapeutics,
Onecell Medical Ltd,
Crispr Therapeutics.
Crispr Stem & Therapeutics Ltd.'s categories are Biotechnology Research
Crispr Stem & Therapeutics Ltd.'s founding year is 2018
